]>
IRCT20190530043769N1 IRCT 2021-01-26 Tabriz University of Medical Sciences The Efficacy of Rivastigmine Augementation to Antipsychotic Agents on Positive and Negative Symptoms and Quality of Life in Patients with Chronic Schizophrenia The Efficacy of Rivastigmine Augementation to Antipsychotic Agents on Positive and Negative Symptoms and Quality of Life in Patients with Chronic Schizophrenia 2021-02-03 anticipated 60 Complete https://irct.ir/trial/39935 interventional Randomization: Not randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Blinding description: Double blind: Participants, Patient care, The responsible person for gathering data, Hospital staff, Data analyzer. 2-3 Chronic schizophrenia. Intervention 1: Interference Group: this group includes chronic schizophrenia patients that receive Rivastigmine capsules (1.5 mg) twice daily along with the previous antipsychotic medication for eight weeks. The medication is produced in Razak factory. Patients will be examined daily regarding the side effects of medication. They will be assessed in three stages; at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality. Intervention 2: Control group: this group includes chronic schizophrenia patients that receive placebo twice daily along with the previous antipsychotic medication for eight weeks. Patients will be examined daily regarding the side effects of medication. They will be assessed in three stages; at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality. Yes - There is a plan to make this available What will be shared: After the clinical study, statistical tests and acquiring the results, the entire stages of study, including: history, method, discussion and conclusion will be shared as thesis and articles in the reputable and relevant journals. When: After being approved by supervisor, advisor and Referees, the thesis will be shared according the norms of Tabriz University of Medical Sciences. To whom: Thesis will be shared according to the norms of library to Tabriz University of Medical Sciences; also, the article will be shared according to the norms of journals. Conditions: The documents will be available according to the norms of university and journals, in order for the scientific community to be aware of the scientific results of this study. Where to obtain: To receive the documents please refer the library of Tabriz University of Medical Sciences. How to obtain: According to the approved stages of Tabriz University of Medical Sciences. Comments:
public Zahra Jahangiri
Tabriz Razi Hospital, Sheikh Mohammad KHiyabani Blvd, Elgoli, Tabriz
Tabriz Iran (Islamic Republic of) 5167846184 +98 41 3380 4486 za.jahangiri1986@gmail.com Tabriz University of Medical Sciences scientific Sepideh Herizchi Ghadim
Tabriz Razi Hospital, Sheikh Mohammad KHiyabani Blvd, Elgoli, Tabriz
Tabriz Iran (Islamic Republic of) 5167846184 +98 41 3380 4486 sherizchi@gmail.com Tabriz University of Medical Sciences Iran (Islamic Republic of) All patients with Chronic Schizophrenia Patients treated with Antipsychotics no limit no limit Both Drug abuse IQ less than 70 ŮŽAnother psychiatric disorder Physical illness ECT in the last two weeks Sensitivity to Rivastigmine F20.0 Paranoid schizophrenia Treatment - Drugs Placebo Interference Group: this group includes chronic schizophrenia patients that receive Rivastigmine capsules (1.5 mg) twice daily along with the previous antipsychotic medication for eight weeks. The medication is produced in Razak factory. Patients will be examined daily regarding the side effects of medication. They will be assessed in three stages; at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality. Control group: this group includes chronic schizophrenia patients that receive placebo twice daily along with the previous antipsychotic medication for eight weeks. Patients will be examined daily regarding the side effects of medication. They will be assessed in three stages; at the start point, after four weeks and at the end of eight weeks, using PANSS questionnaires and life quality. Efficacy of Rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Positive, negative symptoms questionnaire in Chronic schizophrenia patients. Efficacy of rivastigmine. Timepoint: Efficacy of Rivastigmine in three stages: at the start point, after 4 weeks and at the end of study. Method of measurement: Quality of Life Questionnaire in Chronic schizophrenic Patients. Side effect. Timepoint: Two months after starting therapy. Method of measurement: Medical history and examination. Tabriz University of Medical Sciences Approved 2021-01-10 Ethics committee of Tabriz University of Medical Sciences Tabriz Razi Hospital, Sheikh Mohammad KHiyabani Blvd, Elgoli, Tabriz Tabriz East Azarbaijan Iran (Islamic Republic of)